Forecast for HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
NIH will soon offer funding for research to develop non-addictive small molecule and biologic pain treatments, supporting projects from early optimization through Phase I trials as part of the HEAL Initiative.
Funder: National Institutes of Health
Due Dates: February 20, 2029
Funding Amounts: Estimated total program funding: $11,000,000; approximately 3 awards expected.
Summary: Supports preclinical development and optimization of safe, effective, non-addictive small molecule and biologic therapeutics for pain treatment.
Description
This funding opportunity supports research focused on the preclinical optimization and development of non-addictive small molecule and biologic therapeutics to treat pain. The program aims to accelerate promising early-stage therapeutic candidates toward readiness for Phase II clinical trials. Supported activities include lead optimization, early-stage development, IND-enabling studies, biomarker development, preparation and submission of an IND application, and Phase I clinical testing. The program uses a phased, milestone-driven cooperative agreement model with active involvement from NIH program staff in planning and monitoring research progress.
